Dr Rositsa Koleva-Kolarova
Rositsa joined HERC in May 2019 as a senior researcher. Currently she works on a Horizon2020 funded project called HEcoPerMed (Health Economics for Personalised Medicine), which aims to provide guidance on state-of-the-art health economic modelling, and on financing and payment strategies for personalised medicine, to distinguish promises from reality.
Previously she held an appointment as a research fellow in health economics in the Department of Population Health Sciences, School of Population Health & Environmental Sciences, King’s College London. She worked on economic evaluation projects on stratifying antihypertensive treatment according to individuals’ ethnicity background, pharmacogenetics and pharmacogenomics for cardiovascular diseases, and evaluating new models of care (Vanguards).
Rositsa obtained her PhD from the University of Groningen, the Netherlands, and held an appointment as an assistant professor at the Department of Public Health Sciences, Faculty of Public Health, Medical University Pleven, Bulgaria.
Cost-Effectiveness Analysis of Treating Patients With NTRK-Positive Cancer With the Histology-Independent Therapy Entrectinib.
Huygens S. et al, (2022), Value Health
A Comparison of the Content and Consistency of Methodological Quality and Transferability Checklists for Reviewing Model-Based Economic Evaluations.
Lim KK. et al, (2022), Pharmacoeconomics
IT Evaluation of Foundation Healthcare Group NHS Vanguard programme: IT simultaneously an enabler and a rate limiting factor.
Tapuria A. et al, (2022), Informatics for health & social care, 47, 317 - 325
REIMBURSEMENT PATHWAY FOR ADVANCED THERAPY MEDICINAL PRODUCTS IN BULGARIA
Djambazov S. et al, (2022), VALUE IN HEALTH, 25, S472 - S472
TARGETED AND IMMUNOTHERAPIES FOR CANCER - REIMBURSEMENT AND EXPENDITURE IN A SINGLE-PAYER HEALTHCARE SYSTEM IN BULGARIA
Encheva-Malinova M. et al, (2022), VALUE IN HEALTH, 25, S477 - S477